UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 1, 2016

Versartis, Inc.
(Exact name of registrant as specified in its charter)

Delaware 001-36361 26-4106690
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

4200 Bohannon Drive, Suite 250
Menlo Park, California 94025
(Address of principal executive offices)

Registrant’s telephone number, including area code: (650) 963-8580

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure.

Spokespersons of Versartis, Inc. (the “Company”) plan to present the information in the presentation poster attached hereto as Exhibit 99.1 at The Endocrine Society’s 98th Annual Meeting and Expo (ENDO 2016) in Boston, MA on April 1, 2016.

The furnishing of the attached presentation is not an admission as to the materiality of any information therein. The information contained in the poster is summary information that is intended to be considered in the context of more complete information included in the Company’s filings with the Securities and Exchange Commission (the “SEC”) and other public announcements that the Company has made and may make from time to time by press release or otherwise. The Company undertakes no duty or obligation to update or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosures.

The information in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

Item 8.01 Other Events.

On April 1, 2016, the Company announced it will be presenting confirmatory 18-month adherence data from its ongoing Extension Study of somavaratan in children with moderate growth hormone deficiency (GHD) in a poster presentation at The Endocrine Society’s 98th Annual Meeting & Expo (ENDO 2016) in Boston, MA. A copy of the press release regarding this announcement, titled “Versartis Presents Confirmatory 18-Month Adherence Data from Ongoing Somavaratan Extension Study at Late-Breaker Session at ENDO Annual Meeting” is attached as Exhibit 99.2 hereto and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

<table>
<thead>
<tr>
<th>Exhibit No.</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>99.1</td>
<td>Company poster presentation dated April 2016</td>
</tr>
<tr>
<td>99.2</td>
<td>Press release dated April 1, 2016, titled “Versartis Presents Confirmatory 18-Month Adherence Data from Ongoing Somavaratan Extension Study at Late-Breaker Session at ENDO Annual Meeting”</td>
</tr>
</tbody>
</table>
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 1, 2016

Versartis, Inc.

By: /s/ Joshua T. Brumm
   Joshua T. Brumm
   Chief Financial Officer
<table>
<thead>
<tr>
<th>Exhibit No.</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>99.1</td>
<td>Company poster presentation dated April 2016</td>
</tr>
<tr>
<td>99.2</td>
<td>Press release dated April 1, 2016, titled “Versartis Presents Confirmatory 18-Month Adherence Data from Ongoing Somavaratan Extension Study at Late-Breaker Session at ENDO Annual Meeting”</td>
</tr>
</tbody>
</table>
Treatment in Children with Growth Hormone Deficiency (GHD) After 18 Months of At-Home Dosing

Erie Humphries, MBA, F. Nazemi, MPhil, PhD, Nargis Sasanian, MD, PhD, George Bight, MD

Background: Children with GHD are often treated for multiple years with daily injections of recombinant human growth hormone (GH) or long acting technology. Switching to an alternative delivery regimen may improve adherence. The aim of this study was to determine the effectiveness of the SC injection technique, and eDiary use. In-clinic visits were conducted quarterly for patient follow up, eDiary reprogramming, and re-supply of somavaran and ancillary supplies. The eDiary was programmed to provide both assigned injection reminders and dosage adherence alerts, and improve the overall adherence.

Results: Adherence was evaluated at the beginning of the study. 3 children were enrolled in the study; 3 in the weekly group and 2 in the monthly group. The adherence rates were 99.6%, 99.5%, and 99.1% for W, TM, and M, respectively. The overall adherence rate for the study was 99.7%.

Table 1: Injection Adherence to Weekly, Twice-Monthly, and Monthly Somavaran Dosing Regimen

<table>
<thead>
<tr>
<th>Dosing Interval</th>
<th>Adherence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weekly (W)</td>
<td>99.6%</td>
</tr>
<tr>
<td>Twice-Monthly (TM)</td>
<td>99.5%</td>
</tr>
<tr>
<td>Monthly (M)</td>
<td>99.1%</td>
</tr>
</tbody>
</table>

Versartis Presents Confirmatory 18-Month Adherence Data from Ongoing Somavaratan Extension Study at Late-Breaker Session at ENDO Annual Meeting

MENLO PARK, Calif., April 1, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), announced that adherence data from its ongoing Extension Study of somavaratan in children with GHD will be presented today in a late-breaker poster presentation at the Endocrine Society’s 98th Annual Meeting & Expo (ENDO 2016), in Boston, MA. Eric Humphriss, MBA, Vice President of Clinical Operations at Versartis, will discuss the results at the Late Breaker poster session (poster LBFri-01) on Friday, April 1, 2016 from 1:15 p.m. – 3:15 p.m. Eastern Time (ET).

Children diagnosed with GHD are treated for an average duration of seven years with daily injections of rhGH, which is currently the only available therapy for GHD in the US and Europe. Treatment adherence is a known burden for GHD patients; non-compliance with daily injections has been reported in up to 66-77% of adults and children with GHD. Studies have also shown that lack of adherence can negatively impact treatment outcome.

Jay Shepard, Chief Executive Officer, commented, “We are greatly encouraged by these results that show better than 99% adherence using a twice-monthly dosing regimen in the at-home setting. The strong adherence data from the ongoing somavaratan Extension Study highlight the potential for improving patient treatment experiences, and potentially outcomes, with a longer acting form of treatment.”

Highlights from Poster Presentation

- With at-home dosing and over 1600 doses administered at the 3.5 mg/kg twice-monthly dose and schedule, dosing adherence was 99.6%.
- Adherence for all dosing schedules over 18 months of at-home therapy resulted in 99.7% adherence.
- This study provides evidence that somavaratan has the potential to improve long-term adherence to growth hormone treatment in children with GHD.

The Extension Study is a long-term safety study that was initiated in March 2014 as patients completed the Phase 1b/2a clinical trial evaluating somavaratan therapy in treatment-naive, pre-pubertal GHD children. At-home dosing was initiated at the beginning of the Extension Study. For assessment of treatment adherence, dosing events were reported by the caregiver using a smartphone-compatible electronic patient-reported outcome diary (eDiary). The eDiary was programmed to provide both assigned injection volume and timing of injection. Caregivers used the eDiary to report injection volume administered and date of administration.

A Phase 3 trial (called VELOCITY) comparing 3.5 mg/kg twice-monthly somavaratan to daily rhGH using the eDiary to monitor treatment adherence is ongoing (NCT02339090).

Program: Late-Breaking Abstracts

Session: LBFri-01 - LBFri-02-LB Pediatric Endocrinology- Friday

Poster: Poster Board LBFri-01

Location: Hall AB1 (Boston Convention & Exhibit Center)

Dates: Friday, April 1, 2016: 1:15 PM-3:15 PM

The poster can be viewed at: http://ir.versartis.com/common/download/download.cfm?companyid=AMDA-2L9X4V&fileid=883572&filekey=F8DF39FA-799D-4A60-98C0-06C3320E6963&filename=ENDO_2016_Adherence_Poster.pdf and the abstract can be viewed at https://endo.confex.com/endo/2016endo/webprogram/Paper28121.html. Both the poster and abstract are also available online within the "EVENTS AND PRESENTATIONS" ( http://ir.versartis.com/events.cfm ) section of the Company's investor relations website at www.versartis.com.

About Versartis, Inc.
Versartis, Inc. is an endocrine-focused biopharmaceutical company initially developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone in late-stage clinical trials for the treatment of growth hormone deficiency (GHD) in children and adults. Somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance and, therefore, treatment outcomes. Versartis' clinical trials can be found at www.versartistrials.com. For more information on Versartis, visit www.versartis.com.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations concerning, among other things, plans and timing of our clinical trials and the potential for eventual regulatory approval of somavaratan. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: our success being heavily dependent on somavaratan; somavaratan being a new chemical entity; the risk that somavaratan may not have favorable results in clinical trials or receive regulatory approval; potential delays in our clinical trials due to regulatory requirements or difficulty identifying qualified investigators or enrolling patients; the risk that somavaratan may cause serious side effects or have properties that delay or prevent regulatory approval or limit its commercial potential; the risk that we may encounter difficulties in manufacturing somavaratan; if somavaratan is approved, risks associated with its market acceptance, including pricing and reimbursement; potential difficulties enforcing our intellectual property rights; our reliance on our
license of intellectual property from Amunix Operating, Inc. and our need for additional funds to support our operations. We discuss many of these risks in greater detail under the heading "Risk Factors" contained in our Annual Report on Form 10-K for the year ended December 31, 2015, which is on file with the Securities and Exchange Commission (SEC). Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contacts:

Corporate & Investors:
Joshua Brumm
Chief Financial Officer
(650) 963-8582
IR@versartis.com

Corporate Communications:
Christine Labaree
Evergreen Communications
(650) 600-1697
christine@evergreencomms.com

Investors:
Nick Laudico/David Burke
The Ruth Group
(646) 536-7030/7009
nlaudico@theruthgroup.com
dburke@theruthgroup.com